An initiative of Flandersbio

Listed companies

Listed companies

in english

The combined market cap of Belgian SME biotech companies gained top position in the European ranking. The fact that the number of qualifying companies is 2 to 3 times smaller than in other European countries confirms the intrinsic quality of the Belgian public biotech sector.

ThromboGenics

ThromboGenics is dedicated to developing and commercializing new pharmacologic ophthalmic treatments that address important unmet clinical needs.

By meeting this goal ThromboGenics intends to help patients around the world with a new or better treatment for their condition.

ThromboGenics on FlandersBio.be

 

Chart IPO Statistics Pipeline Contact

Click on the chart to follow the daily exchange rate.

View the NYSE Euronext chart

  • Listing date:   06/07/2006

View chart De Tijd

Product Indications and progress Partner
JETREA(R) (ocriplasmin) Symptomatic VMA/ VMT Commercialized: US (directly)/ ex-US with Alcon
 
JETREA(R) (ocriplasmin) Diabetic Retinopathy Phase II in planning : first patient in planned for H2 2015
 
JETREA(R) (ocriplasmin) RVO (Retinal Vein Occlusion) Pre-clinical
 
TG-758 Diabetic Eye Disease Pre-clinical with Bicycle Therapeutics
 
TG-931 Diabetic Eye Disease Pre-clinical with Eleven Biotherapeutcis
 
THR-317 (anti-PlGF) Diabetic Eye Disease Pre-clinical (owned)
 
TB-403 Oncology Phase I/IIa – Oncurious
 

Investor Relations:
Wouter Piepers , Global Head of Corporate Communications & IR
Email:
Phone: +32 (0) 16 75 13 10

Address details:
Bio-incubator, Gaston Geenslaan 1, 3001 Leuven, Belgium
Website: http://www.thrombogenics.com
Email:

Back to top

Print